

Guidance for the Use of Non-oral Steroids with Strong CYP3A4 Inhibitors

Revised October 2022

Page 1 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Recommendations for non-oral steroids with strong CYP3A4 inhibitors

		Preferred	Not Recommended	Do Not Coadminister	Follow Up
Drugs for HIV					
Any combination containing any of the following: <ul style="list-style-type: none"> • Atazanavir • Cobicistat • Darunavir • Lopinavir • Ritonavir 	<i>Inhaled</i>	Beclometasone		Budesonide Fluticasone Mometasone	Periodic control of morning cortisol
	<i>Nasal</i>	Beclometasone		Budesonide Fluticasone Mometasone	
	<i>Intra-articular or epidural</i>	Prednisolone (30% dose reduction required) Methylprednisolone (at least 50% dose reduction required)		Triamcinolone	
	<i>Topical</i>	Hydrocortisone	Clobetasol Betamethasone		
Any other HIV drug combinations		Check with pharmacist	Check with pharmacist	Check with pharmacist	Check with pharmacist
Drugs for Hepatitis C					
Any DAA combination containing the following: <ul style="list-style-type: none"> • Paritaprevir/ritonavir 	<i>Inhaled Nasal Intra-articular or epidural Topical</i>	Same recommendations as for HIV protease inhibitors and pharmacokinetic boosters	Same recommendations as for HIV protease inhibitors and pharmacokinetic boosters	Same recommendations as for HIV protease inhibitors and pharmacokinetic boosters	Periodic control of morning cortisol
Others					
Any potent CYP3A4 inhibitor (particularly in case of long term treatment) including: <ul style="list-style-type: none"> • Clarithromycin • Erythromycin • Itraconazole • Ketoconazole • Posaconazole • Voriconazole 	<i>Inhaled Nasal Intra-articular or epidural Topical</i>	Same recommendations as for HIV protease inhibitors and pharmacokinetic boosters	Same recommendations as for HIV protease inhibitors and pharmacokinetic boosters	Same recommendations as for HIV protease inhibitors and pharmacokinetic boosters	Periodic control of morning cortisol


Guidance for the Use of Non-oral Steroids with Strong CYP3A4 Inhibitors

Revised October 2022

Page 2 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Management of patients with a suspected steroid-CYP3A4 inhibitor interaction



* Depending on local assay

Adapted with permission from Elliot ER et al. Clin Med, 2016, 16: 412-418

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.